Cytokinetics (CK-3773274)

Summary

This study focuses on adults who have obstructive hypertrophic cardiomyopathy (oHCM), abnormally thick heart muscle, and left ventricular outflow tract (LVOT) obstruction (a condition which interferes with the flow of blood in the heart). The study is designed to evaluate the tolerability and safety of an investigational drug called CK-3773274. CK-3773274 may reduce symptoms of oHCM by reducing LVOT obstruction. The study will compare the effects of CK-3773274 with placebo (inactive substance) to learn how well the drug is tolerated in patients with oHCM and whether it causes any side effects. The study will also examine the amount of CK-3773274 in the blood at various times and the effect it may have on the patient's oHCM. Additionally, researchers aim to determine the optimal dose level of CK-3773274.


Inclusion Criteria

  • Males and females (of non-childbearing potential) between 18 and 55 years of age, inclusive
  • Body weight > 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive
  • Normal cardiac structure and function, or if abnormalities are present, they are deemed not clinically significant
  • Normal to high left ventricular ejection fraction.
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

Details
Disease Type/Condition

Genetic Disorders of the Cardiovascular System, Heart failure

Principal Investigator

Rader, Florian

Co-Investigators

Michele Hamilton, Michele Hamilton, Robert Siegel

Age Group

Adult

Phase

II

IRB Number

STUDY00000362

ClinicalTrials.gov ID

NCT03767855

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Genetic Disorders of the Cardiovascular System, Heart failure

Principal Investigator

Rader, Florian

Age Group

Adult

Phase

II

IRB Number

CY6021

ClinicalTrials.gov ID

NCT03767855

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?